A paper published in the September issue of Annals of Surgery found that Irreversible Electroporation performed on 200 patients with locally advanced pancreatic cancer had prolonged their survival. The procedure used Latham-based AngioDynamics’ NanoKnife technology. The study was partially funded by a grant from AngioDynamics.
The study’s goal was to “evaluate the effectiveness of IRE as a consolidative therapy in combination with chemotherapy and/or chemoradiation therapy in the management of LAPC.”
The NanoKnife removes soft tissue with a series of high-voltage, low-energy electrical pulses. It is approved by the U.S. Food and Drug Administration for use in the removal of soft tissue but not as a therapy or treatment for any specific disease or condition, the company said.
AngioDynamics is headquartered in Latham, with local manufacturing operations in Queensbury.
An abstract of the article is available here.
No comments:
Post a Comment